Table 1:
Clinic characteristics of the discovery and validation cohorts.
| Characteristics | Discovery cohort (n=1157) |
US cohort (n=2149) |
European cohort (n=833) |
|---|---|---|---|
| Age (yr) | 65.0(55–72) | 62.9(55–71) | 75.0(66–81) |
| Male (%) | 63.6 | 64.0 | 70.1 |
| BMI (kg/m2) | 29.2(25.5–32.2) | 29.4(25.4–32.1) | NA |
| Diabetes mellitus (%) | 22.0 | 22.1 | 27.9 |
| Hypertension (%) | 72.2 | 70.4 | 80.4 |
| Current smoking (%) | 13.7 | 12.7 | 16.8 |
| Coronary artery disease (%) | 75.5 | 75.0 | 69.3 |
| Heart failure (%) | 16.7 | 19.4 | 17.8 |
| History of myocardial infarction (%) | 46.3 | 39.5 | 49.6 |
| Low-density lipoprotein (mg/dl) | 96.0(80.0–115.0) | 96.0(77.0–117.0) | 91.5(69.0–122.0) |
| High-density lipoprotein (mg/dl) | 34.3(28.5–41.2) | 34.3(28.2–41.7) | 48.0(39.0–60.0) |
| Total cholesterol (mg/dl) | 163.8(142.7–188.2) | 160.8(138.5–187.4) | 161.0(134.8–195.0) |
| Triglycerides (mg/dl) | 122.0(84.0–171.0) | 114.0(84–163) | 118.0(89.0–167.0) |
The baseline characteristics of participants in the discovery cohort, and both validation cohorts (US, and European) are shown. Continuous data are presented as median (25th and 75th percentiles). Categorical variables are presented as %.